Abstract
11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) is mainly distributed in the human liver with no detectable levels in the intestine or kidney based on a newly developed proteomic approach. 11β-HSD1 is mostly membrane bound and retained in the liver microsomal faction. Inter-individual variability of 11β-HSD1 is relatively low with about a three-fold difference. A significant correlation was not observed between various demographic variables (ethnicity, gender, age, weight, smoking, and alcohol use) and 11β-HSD1 protein expression or activity based on data from thirty-one donors. PF-915275 has been identified as a selective 11β-HSD1 inhibitor with minimal effects on carbonyl reductase 1 and major cytochrome P450 enzymes. 11β-HSD1 has been shown, for the first time, to be involved in doxorubicin metabolism accounting for approximately 30% of doxorubicinol formation in human hepatocytes.
- drug design
- drug development/discovery
- drug toxicity
- enzyme inhibitors
- enzyme kinetics
- hepatocytes
- HPLC
- mass spectrometry/MS
- proteomics
- reductases
- The American Society for Pharmacology and Experimental Therapeutics